Business
Milestone Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Corporate Update
- RAPID topline data readout remains on track for mid-second half 2022 - Results from NODE-302 study highlights etripamil safety and reduced need for ED
About this update from Milestone Pharmaceuticals Inc.
[{"type":"text","content":"- RAPID topline data readout remains on track for mid-second half 2022\n- Results from NODE-302 study highlights etripamil safety and reduced need for ED interventions\nMONTREAL and CHARLOTTE, N.C., May 12, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the first quarter ended March 31, 2022, and provided a clinical and corporate update.\n\"The beginning of 2022 has been a productive time for Milestone, marked by continued progress advancing our lead Phase 3 program, etripamil, for patients with PSVT,\" said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals. \"Of note, we were particularly excited by the recent presentation of NODE-302 at the Heart Rhythm Society's Heart Rhythm 2022 conference which highlighted data that continued to support the potential of etripamil as a self-treatment option for patients with PSVT, including those patients experiencing multiple episodes. We remain optimistic for the eventual safety profile of etripamil as clinical trial experience with the repeat dose regimen grows, and we look forward to reporting topline results from our Phase 3 RAPID trial in the middle of the second half of 2022.\"\nRecent Updates\nCompany Remains on Track to Report Topline Data from RAPID Trial in Mid-Second Half 2022. The RAPID trial, in which patients are randomized 1:1 to receive either etripamil or placebo, is targeting a total of 180 confirmed PSVT events. To maximize the potential treatment effect of etripamil, patients are directed to administer a repeat dose of study drug if they do not experience symptom relief within 10 minutes of the first dose. The primary efficacy analysis for both the RAPID trial and the completed NODE-301 trial will be time to conversion of supraventricular tachycardia (SVT) over the first 30 minutes following initial study drug administration, with a target p-value of less than 0.05 for each trial. The RAPID and NODE-301 trials could potentially serve to fulfill the efficacy requirement for a future New Drug Application submission for etripamil in patients with PSVT.Data from Phase 3 NODE-302 Open-Label Extension Study of Etripamil for the Treatment of PSVT Presented at Heart Rhythm 2...